High CDK8 expression significantly decreased relapse-free survival in treatment-naïve patients with prostate cancer (TCGA database), whereas CDK19 expression did not [Fig. 5B, Supplementary Fig. S9 (25)]. This evidence concerns the gene CDK8 and Familial prostate cancer.